Study design and clinical response. (A) Study design. (B) Organ-specific cGVHD scores at baseline and week 8 (W8). ∗Patient 17 also had liver involvement that met PR criteria by 50% decrease in the ALT value (97 U/L at baseline, 48 U/L at week 8). +Patient 18 had polyserositis as the sole manifestation of cGVHD. #Patient 2 had lung progression based on FEV1 59% predicted at baseline and FEV1 43% at week 8 (decrease by 10% predicted absolute value of %FEV1). ALT, alanine aminotransferase; FEV, forced expiratory volume; GI, gastrointestinal; GSS, global severity score; JMF, joint/muscle/fascia; PR, partial response; SD, stable disease; SD/MR, stable disease with minor response; PD, progressive disease; NA, not applicable.